Tharimmune Executives

Tharimmune Management Team Effectiveness

The company has return on total asset (ROA) of (0.9979) % which means that it has lost $0.9979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2501) %, meaning that it created substantial loss on money invested by shareholders. Tharimmune's management efficiency ratios could be used to measure how well Tharimmune manages its routine affairs as well as how well it operates its assets and liabilities. Tharimmune shows a total of 39.53 Million outstanding shares. Tharimmune maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Tharimmune in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tharimmune, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Tharimmune Workforce Comparison

Tharimmune Insider Trading

Tharimmune Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Tharimmune often depends on how effective the management is. Tharimmune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tharimmune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tharimmune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.

If you are still planning to invest in Tharimmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tharimmune's history and understand the potential risks before investing.